PHP48 THE EFFECTS OF NICE HTA'S ON PRESCRIPTION VOLUME, AVERAGE RETAIL PRICE AND AVERAGE OUT-OF-POCKET COSTS OF DRUGS DEEMED MEDICALLY NECESSARY FOR MEDICARE PART D REIMBURSEMENT IN THE UNITED STATES  by Sepulveda, B et al.
opment of treatments for rare diseases. This has resulted in 515
EU designations for orphan medicinal products in June 2008.
Many orphan drugs (ODs) receive market authorisation,
however there are problems regarding access and reimbursement.
This study compares OD policies and examines the reimburse-
ment of ODs across Europe. METHODS: Policies on ODs in
European countries for which sufﬁcient detail had been published
were examined. HTA websites were searched for assessments on
ODs and data extracted on the recommendations. RESULTS: In
some countries, including Sweden and The Netherlands, ODs
may be approved for reimbursement with minimal documenta-
tion of cost-effectiveness. However, many countries, including
England and Scotland do not have speciﬁc polices for the
appraisal and reimbursement of ODs. This results in many
patients across Europe who do not see any beneﬁt from the
orphan product legislation. By April 2008, 45 drugs with desig-
nated OD status had been given European marketing authorisa-
tion in 42 different indications. Thirty-seven submissions had
been assessed by the SMC by June 2008 according to the stan-
dard appraisal procedures, with 4 accepted for use, 13 accepted
for restricted use and 20 not recommended in NHS Scotland
(11%, 35% and 54%, respectively). This contrasts with previ-
ously published data on recommendations from the SMC; 30%
approved, 35% restricted, 36% not recommended (Karia et al.
2008). Furthermore, by June 2008, NICE had only assessed 2
OD indications, with 4 ODs currently undergoing assessment
and 3 proposed as topics for assessment. CONCLUSIONS: The
granting of market authorisation by the EMEA does not always
lead to reimbursement of a drug; patient access to ODs varies
across different European countries.
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OBJECTIVES: The quantity of research generated is increasing
yearly. It is of interest to determine the types of research being
published to assess the content of the current knowledge base.
Research can be categorized as randomized controlled trials
(RCTs), observational studies (OS), systematic reviews (SR), or
economic studies (ES). Our aim was to determine the proportion
of research being conducted in these categories and to assess the
relative proportions of each across time. METHODS: A citation
search was conducted in Medline on 18 June 2008. Search ﬁlters
for RCTs, OS, SR, and ES were implemented to provide an
estimate of research conducted in these categories for the years
1950–2007. The prevalence of each type of research was calcu-
lated and changes over time were analysed using logistic regres-
sions. RESULTS: The total probable citations retrieved were:
740 599 for RCTs, 1 217 246 for OS, 1 287 915 for SR, and
325 625 for ES. The proportion of research conducted for each
of these overall was 20.7%, 34.1%, 36.1%, and 9.1%, respec-
tively. From 1977 to 2007 there was a 12-fold increase in prob-
able RCTs, a 15-fold increase in both probable OS and SR, and
a 9-fold increase in probable ES. Logistic regression analysis
showed a signiﬁcant association between category and time
(p < 0.0005). CONCLUSIONS: The majority of research being
conducted appears to be focused on OS or reviews of the litera-
ture. In contrast, probable RCTs and ES, which are arguably the
most useful and rigorous forms of research, together consist of
less than one third of the research being conducted. Furthermore,
the increase in this research during the previous 30 years is lower
than that of OS and SR. It is possible that the focus on SR reﬂects
the growing recognition of the importance of this literature
searching technique.
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LIFE AND HEALTH SERVICE UTILIZATION AMONG PRIMARY
CARE PATIENTS
Chen T, Li L
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OBJECTIVES: We aim to investigate uncontrolled associations
between HRQOL and health services utilization among primary
care patients in mainland China. METHODS: A retrospective
cross-sectional design was carried out among patients consulting
in primary care in mainland China. Health services utilization
was measured by the number of monthly outpatient consultation
and the annual hospitalization rate. HRQOL was measured by
either electronic or paper version of the Chinese SF-36. The
clustered model was adapted to calculate the independent con-
tributions from scores of the SF-36 subscales. A total of 733 valid
subjects were eventually recruited for this study. RESULTS: The
score of MH has a negative association with the number of
monthly outpatient consultation and its independent contribu-
tion explained within the clustered model was 7.0%, whereas
both the score of GH and PF have negative associations with the
annual hospitalization rate and the independent contributions
from GH and PF was a total of 22.2%. CONCLUSIONS: In
summary, this was the ﬁrst study verifying that scores of the
SF-36 subscales have negative associations with outpatient and
inpatient consultation among primary care patients in mainland
China.
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OBJECTIVES: As Medicare Part D results in de facto centraliza-
tion of buying power in the US, we hypothesized that NICE
HTA’s would increasingly inﬂuence the US market. The primary
objective is to determine whether major ﬁndings of Health Tech-
nology Appraisals (HTAs) by the National Institute for Clinical
Excellence (NICE; UK) impacted US trends in prescription
volume, retail price and out-of-pocket costs of statins and of six
therapeutic classes deemed medically necessary for Medicare
beneﬁciaries. As a point of reference, we sought to investigate the
same market factors in relation to the index date of Medicare
Part D introduction. METHODS: The two most prescribed
statins (atorvastatin, simvastatin), anticonvulsants (clonazepam,
gabapentin), antidepressants (escitalopram, ﬂuoxetine), oral
antineoplastics (capecitabine, imatinib), antipsychotics (quetiap-
ine, risperidone), immunosuppressants (azathioprine, mycophe-
nolate), and antiretrovirals (emtricitabine/tenofovir, ritonavir)
were selected based on total prescriptions (TRx). TRx, average
retail price (ARP) and average out-of-pocket costs (OPC) per
prescription were collected quarterly for 2005–2008. For six
related HTAs conducted by NICE and the implementation of
Medicare Part D, TRx, ARP and OPC were analyzed for the
same number of quarters before and after the index event.
Parameters were collected using Verispan’s VONA and VOPA
databases. Statistical analyses were performed using one-way
ANOVA. RESULTS: From 2005 to 2008, 7 of the 14 drugs
analyzed were directly or indirectly covered by a NICE HTA.
Two HTAs were correlated with a signiﬁcant increase in TRx,
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four with a signiﬁcant increase in ARP, and two with a signiﬁcant
increase in OPC (p < 0.05). By comparison, Medicare Part D
resulted in signiﬁcant TRx increases for ten drugs (and no
decreases), eight showed ARP increases and two had ARP
decreases (p < 0.05). Interestingly, seen drugs decreased OPC
while two increased (p < 0.05). CONCLUSIONS: NICE HTAs
had mild effects on the prescription utilization and costs in the
US, while Medicare Part D caused fundamental changes to the
market parameters measured. The inﬂuence of NICE decisions
on the US market should be monitored as HTAs are expected to
play a more signiﬁcant role in the advent of Medicare Part D
Reimbursement.
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OBJECTIVES: Health technology assessment is used to inform
reimbursement decisions for pharmaceuticals in many countries.
The political and administrative contexts in which HTA is used
vary considerably between countries, as do the decisions on
individual products. The aim of this study was to investigate the
inﬂuence of HTA and other factors on reimbursement decisions.
METHODS: A systematic search was conducted to obtain the
documentation for reimbursement decisions on cancer and car-
diovascular medicines. Where insufﬁcient information was pub-
lished, or reports were not available in English, decisions were
excluded. The analysis was conducted using discrete response
models and included methods of assessment, evidence included
and stakeholder involvement. RESULTS: Detailed information
was obtained on 194 decisions from Australia, Belgium, Canada,
England, France, Scotland and Sweden. The pooled analysis
showed that 27% of medicines were recommended, 41% were
recommended for restricted use and 32%were not recommended.
The multinomial logistic regression showed that the number of
RCTs, disease area, use of sensitivity analysis and public interest
had a statistically signiﬁcant impact upon decisions. The use of
cost-utility analysis in the supporting HTA was found to reduce
the probability of a positive recommendation. The analysis for
those countries that included cost-utility analysis showed that the
value of the ICER had a statistically insigniﬁcant impact upon the
decision.However, a sub-analysis for decisions in England showed
that this was found to be statistically signiﬁcant. CONCLU-
SIONS:These ﬁndingsmay reﬂect varying approaches to conduct-
ing economic analysis, differences in cost-effectiveness thresholds
and variation in the weight given to economic evidence in inform-
ing decisions within countries. The individual product level
factors explain some of the variation in reimbursement decisions
across countries. Further variationmay be explained by the health
system and policy context in which decisions are made. The next
stage of the work will investigate these factors directly.
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OBJECTIVES: Early-stage medical technology assessment
(MTA) is sometimes conducted in an ad-hoc manner, if it is
performed at all. Identiﬁcation of universal steps in early-stage
MTA would catalyze the development of valuable technology.
METHODS: Universal steps in early-stage MTA were developed
following evaluation of a new stroke rehabilitation strategy tar-
geting the urban Chinese population. Literature review, physician
and patient interviews, and decision modelling were performed
to appraise current stroke care and evaluate methods to improve
it. Different rehabilitation strategies were recognised and
described, and their costs and health effects were estimated and
compared. RESULTS: Certain universal steps in early-stage MTA
could be identiﬁed. An important ﬁrst step is the creation of a
detailed study plan that includes evaluation criteria and may also
discuss the value of a disease progression model. A second step
consists of qualitative and quantitative descriptions of current
treatments and new technologies. This step focuses not simply
on acquiring quantitative estimates of costs, health effects and
quality of care, but also on identifying areas for quality improve-
ment. Since the literature review did not yield sufﬁcient informa-
tion, other methods (i.e., interviews) were needed to ascertain
attitudes regarding usual care and behaviour. These methods
provided extra insight into physician and patient preferences,
insight that was used to modify the evaluation criteria. Subse-
quently, the new technology was described both qualitatively and
quantitatively. Lastly, the costs and health effects of the treat-
ments were compared using standard techniques (e.g., uncer-
tainty analysis). These results identiﬁed where more information
needed to be collected. CONCLUSIONS: As with later-stage
MTA, there is a need and an opportunity to develop universal
steps for conducting early-stage MTA. They supplement, but do
not replace, the steps and techniques applied during later-stage
assessments. If properly formulated, they can be used to facilitate
good internal decision-making during the development phase.
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OBJECTIVES: In England only new innovative technologies
evaluated useful and cost effective are taken up by health care
providers. NICE leads the way for this managed entry, but delays
in publication of guidance, and the fact it only covers tech-
nologies with the potential to have large ﬁnancial impact, leaves
local payers looking to other technology appraisal groups for
guidance—often local groups, to review a technology in line with
local needs, demographics and priorities. There are more than 30
of these review groups operating in England, on either a national
or local level which inﬂuence prescribing, funding, and commis-
sioning decisions. This research was undertaken to understand,
and map the inﬂuence of these organizations. METHODS: A
total of 65 senior mangers from SHAs, PCTs, hospital Trusts, and
HTA organsiations were interviewed, using qualitative and quan-
titative measures, to provide an indication of the current, and
future inﬂuence of HTA organizations in England. RESULTS:
For interventions without forthcoming NICE guidance, NHS
organizations are responsible for accessing publicly available
evidence to determine local policies for managed entry. Notiﬁca-
tion of new drugs is generally from one of the national informa-
tion portals. In the absence of NICE guidance, the SMC is, for
most, the next port of call. If there is no NICE, or SMC guidance,
HCPs generally look to their regional group, or the HTA group
with relevant therapy experience. The remit, focus and inﬂuence
of the different regional groups was assessed and found to vary.
CONCLUSIONS: Because of delays in NICE guidance of up to
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